Navigation auf uzh.ch
Navigation auf uzh.ch
Newsletter Long COVID Newsletter 02 / November 2023
First Press Release https://longcovidproject.eu/2023/10/09/3rd-long-covid-press-release/
Weitere Infos zum EU-Projekt "Long Covid" finden Sie unter https://longcovidproject.eu/
Dieses Projekt wird vom Forschungs- und Innovationsprogramm Horizon Europe der Europäischen Union unter der Finanzhilfevereinbarung Nr. 101057553 und vom Schweizer Staatssekretariat für Bildung, Forschung und Innovation (SBFI) unter der Vertragsnummer 22.00094 unterstützt.
Ein Team des IVPZ unter der Leitung von Prof. Anja Kipar ist beteiligt an einem von der European Commission zugesprochenen „Horizon Europe“-Projekt zu Long COVID: https://www.hus.fi/en/newsroom/significant-eu-funding-hus-helsinki-university-hospital-led-research-project-long-term
Die UZH berichtet über das Projekt und die Arbeit von Prof. Kipar in einer Science Story: https://science-stories.ch/kipar/?lang=de
Gallardo-Toledo E, Neary M, Sharp J, Herriott J, Kijak E, Bramwell C, Curley P, Arshad U, Pertinez H, Rajoli RKR, Valentijn A, Cox H, Tatham L, Kipar A, Stewart JP, Owen A, 2023. Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters. Viruses 2023, 15, 2161. Also released at MDPI: https://www.mdpi.com/1999-4915/15/11/2161
Neary M, Sharp J, Gallardo-Toledo E, Herriott J, Kijak E, Bramwell C, Cox H, Tatham L, Box H, Curley P, Arshad U, Rajoli RKR, Pertinez H, Valentijn A, Dhaliwal K, Mc Caughan F, Hobson J, Rannard S, Kipar A, Stewart JP, Owen A, 2023. Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. Viruses 2023, 15, 1744. Also released at MDPI: https://www.mdpi.com/1999-4915/15/8/1744
De Neck S, Penrice-Randal R, Clark JJ, Sharma P, G Bentley E, Kirby A, Mega DF, Han X, Owen A, Hiscox JA, Stewart JP, Kipar A, 2023. The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses 2023, 15, 1637. Also released at MDPI: https://www.mdpi.com/1999-4915/15/8/1637
Kant R, Kareinen L, Ojha R, Strandin T, Saber SH, Lesnikova A, Kuivanen S, Sirnonen T, Joensuu M, Vapalahti O, Kirchhausen T, Kipar A, Balistreri G, 2023. Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors. 2023 Jul 20. doi: 10.1101/2023.07.19.549731. Online ahead of print. Also released at bioRxiv. https://www.biorxiv.org/content/10.1101/2023.07.19.549731v1
Freitag TL, Fagerlund R, Karam NL, Leppänen VM, Ugurlu H, Kant R, Mäkinen P, Tawfek A, Jha SK, Strandin T, Leskinen K, Hepojoki J, Kesti T, Kareinen L, Kuivanen S, Koivulehto E, Sormunen A, Laidinen S, Khattab A, Saavalainen P, Meri S, Kipar A, Sironen T, Vapalahti O, Alitalo K, Ylä-Herttuala S, Saksela K. 2023. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models. Vaccine 2023, 41(20), 3233-3246. Also released at Sciencedirct: https://www.sciencedirect.com/science/article/pii/S0264410X23004036?via%3Dihub
Mäkelä AR, Uğurlu H, Hannula L, Salminen P, Kant R, Fagerlund R, Haveri A, Strandin T, Kareinen L, Hepojoki J, Levanov L, Pasternack A, Naves RA, Ritvos O, Österlund P, Sironen T, Vapalahti O, Kipar A, Huiskonen JT, Rissanen I, Saksela K. 2023. Intranasal inhibitor blocks Omicron and other variants of SARS-CoV-2. Nat Commun. 2023, 14(1), 1637.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037368/pdf/41467_2023_Article_37290.pdf
Tatham L, Kipar A, Sharp J, Kijak E, Herriott J, Neary M, Box H, Toledo EG, Valentijn A, Cox H, Pertinez H, Curley P, Arshad U, Rajoli RKR, Rannard S, Stewart J, Owen A, 2023. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. BioRxiv. https://www.biorxiv.org/content/10.1101/2022.01.23.477397v2
Seehusen F, Clark JJ, Sharma P, Bentley EG, Kirby A, Subramaniam K, Wunderlin-Giuliani S, Hughes GL, Patterson EI, Michael BD, Owen A, Hiscox JA, Stewart JP, Kipar A, 2022. Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse. Viruses 2022, 14, 1020. Also released at MDPI: http://www.mdpi.com/1999-4915/14/5/1020
Kant R, Kareinen L, Smura T, Freitag TL, Jha SK, Alitalo K, Meri S, Sironen T, Saksela K, Strandin T, Kipar A, Vapalahti O, 2021. Common laboratory mice are susceptible to infection with SARS-CoV2 beta variant. Viruses 2021, 13, 2263https://www.mdpi.com/1999-4915/13/11/2263
Huo J, Mikolajek H, Le Bas A, Clark JJ, Sharma P, Kipar A, Dormon J, Norman C, Weckener M, Clare DK, Harrison PJ, Tree JA, Buttigieg KR, Salguero FJ, Watson R, Knott D, Carnell O, Ngabo D, Elmore MJ, Fotheringham S, Harding A, Moynié L, Ward PN, Dumoux M, Prince T, Hall Y, Hiscox JA, Owen A, James W, Carroll MW, Stewart JP, Naismith JH, Owens RJ, 2021. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Comun 2021, 12, 5469 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458290/pdf/41467_2021_Article_25480.pdf
Salzer R, Clark JJ, Vaysburd M, Chang VT, Albecka-Moreau A, Kiss L, Sharma P, Gonzalez Llamazares A, Kipar A, Hiscox JA, Owen A, Aricescu AR, Stewart JP, James LC, Löwe J, 2021. Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice. FEBS Lett. 2021 Jul 31. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.14171
Klaus J, Zini E, Hartmann K, Egberink H, Kipar A, Bergmann M, Palizzotto C, Zhao S, Rossi F, Franco V, Porporato F, Hofmann-Lehmann R, Meli ML, 2021. SARS-CoV-2 Infection in Dogs and Cats from Southern Germany and Northern Italy during the First Wave of the COVID-19 Pandemic. Viruses 2021, 13, 1453. https://www.mdpi.com/1999-4915/13/8/1453
Wang Y, Sharma P, Jefferson M, Zhang W, Bone B, Kipar A, Bitto D, Coombes JL, Pearson T, Man A, Zhekova A, Bao Y, Tripp RA, Carding SR, Yamauchi Y, Mayer U, Powell PP, Stewart JP, Wileman T, 2021. Non-canonical autophagy functions of ATG16L1 in epithelial cells limit lethal infection by influenza A virus. EMBO J. 2021, 40, e105543. http://www.embopress.org/doi/full/10.15252/embj.2020105543
Clark JJ, Penrice-Randal R, Sharma P, Kipar A, Dong X, Davidson A, Kavanagh Williamson M, Matthews DA, Turtle L, Prince T, Hughes GL, Patterson EI, Shawli G, Subramaniam K, Sharp J, McLaughlin L, Zhou E-M, Turner JD, Marriott AE, Colombo S, Pennington SH, Biagini G, Owen A, Hiscox JA, Stewart JP, 2021. Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. BioRxiv. https://www.biorxiv.org/content/10.1101/2020.10.13.334532v2).
Clark JJ, Sharma P, Bentley EG, Harding AC, Kipar A, Neary M, Box H, Hughes GL, Patterson EI, Sharp J, de Oliveira T, Sigal A, Hiscox JA, James WS, Carroll MW, Owen A, Stewart JP, 2021. Naturally-acquired immunity in Syrian Golden Hamsters provides protection from re-exposure to emerging heterosubtypic SARS-CoV-2 variants B.1.1.7 and B.1.351. BioRxiv. https://www.biorxiv.org/content/10.1101/2021.03.10.434447v1.
Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R, Prince T, Brown JC, Zhou J, Screaton GR, Barclay WS, Owen A, Hiscox JA, Stewart JP. 2021. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 https://www.biorxiv.org/content/10.1101/2021.12.26.474085v2.
